Authors: Montefiori, DC Safrit, JT Lydy, SL Barry, AP Bilska, M Vo, HTT Klein, M Tartaglia, J Robinson, HL Rovinski, B

Citation: Dc. Montefiori et al., Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques, J VIROLOGY, 75(13), 2001, pp. 5879-5890

Authors: Murdin, AD Rovinski, B Sambhara, S

Citation: Ad. Murdin et al., Inactivated virus vaccines, MED INTEL U, 26, 2001, pp. 133-150

Authors: Arp, J Rovinski, B Sambhara, S Tartaglia, J Dekaban, G

Citation: J. Arp et al., Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions, VIRAL IMMUN, 12(4), 1999, pp. 281-296

Authors: Rovinski, B Dekaban, GA Cao, SX Yao, FL Persson, R Matthews, TJ Klein, MH

Citation: B. Rovinski et al., Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguishedfrom HIV-1 infectees, VIROLOGY, 257(2), 1999, pp. 438-448

Authors: Garnier, L Parent, LJ Rovinski, B Cao, SX Wills, JW

Citation: L. Garnier et al., Identification of retroviral late domains as determinants of particle size, J VIROLOGY, 73(3), 1999, pp. 2309-2320

Authors: Persson, RH Cao, SX Cates, G Yao, FL Klein, MH Rovinski, B

Citation: Rh. Persson et al., Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity, BIOLOGICALS, 26(4), 1998, pp. 255-265